DK144560B - Analogifremgangsmaade til fremstilling af (1-hydroxy-5-indanyloxy) eddikesyrer eller salte deraf med baser - Google Patents
Analogifremgangsmaade til fremstilling af (1-hydroxy-5-indanyloxy) eddikesyrer eller salte deraf med baser Download PDFInfo
- Publication number
- DK144560B DK144560B DK506874AA DK506874A DK144560B DK 144560 B DK144560 B DK 144560B DK 506874A A DK506874A A DK 506874AA DK 506874 A DK506874 A DK 506874A DK 144560 B DK144560 B DK 144560B
- Authority
- DK
- Denmark
- Prior art keywords
- hydroxy
- dichloro
- indanyloxy
- methyl
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- -1 1-HYDROXY-5-INDANYLOXY Chemical class 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001243 acetic acids Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
- 239000000460 chlorine Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- 239000002934 diuretic Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000001882 diuretic effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- 238000000921 elemental analysis Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- VQWPLVDFJOEXQY-UHFFFAOYSA-N 6,7-dichloro-2-(4-chlorobutyl)-5-methoxy-2,3-dihydroinden-1-one Chemical compound ClC1=C(Cl)C(OC)=CC2=C1C(=O)C(CCCCCl)C2 VQWPLVDFJOEXQY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000003424 uricosuric effect Effects 0.000 description 3
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 2
- WXQGODUEDHXRKN-UHFFFAOYSA-N 2-[(6,7-dichloro-2-ethyl-1-hydroxy-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=C(Cl)C(Cl)=C2C(O)C(CC)CC2=C1 WXQGODUEDHXRKN-UHFFFAOYSA-N 0.000 description 2
- FNKRIDAPUUDBPN-UHFFFAOYSA-N 6,7-dichloro-5-hydroxy-2-methyl-2-phenyl-3h-inden-1-one Chemical compound C1C2=CC(O)=C(Cl)C(Cl)=C2C(=O)C1(C)C1=CC=CC=C1 FNKRIDAPUUDBPN-UHFFFAOYSA-N 0.000 description 2
- ARIBNFLJQYPMIT-UHFFFAOYSA-N 6,7-dichloro-5-methoxy-2-methyl-2-phenyl-3h-inden-1-one Chemical compound O=C1C=2C(Cl)=C(Cl)C(OC)=CC=2CC1(C)C1=CC=CC=C1 ARIBNFLJQYPMIT-UHFFFAOYSA-N 0.000 description 2
- APXPIMBLURJCDR-UHFFFAOYSA-N 6-bromo-1-(2,3-dichloro-4-methoxyphenyl)hexan-1-one Chemical compound COC1=CC=C(C(=O)CCCCCBr)C(Cl)=C1Cl APXPIMBLURJCDR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- HFEASCCDHUVYKU-UHFFFAOYSA-N 1,2-dichloro-3-methoxybenzene Chemical compound COC1=CC=CC(Cl)=C1Cl HFEASCCDHUVYKU-UHFFFAOYSA-N 0.000 description 1
- RTCUCQWIICFPOD-UHFFFAOYSA-N 1-naphthalen-1-ylethanamine Chemical compound C1=CC=C2C(C(N)C)=CC=CC2=C1 RTCUCQWIICFPOD-UHFFFAOYSA-N 0.000 description 1
- SZOLGWAHEZEMMN-UHFFFAOYSA-N 2-[(6,7-dichloro-2-ethyl-1-oxo-2,3-dihydroinden-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=C(Cl)C(Cl)=C2C(=O)C(CC)CC2=C1 SZOLGWAHEZEMMN-UHFFFAOYSA-N 0.000 description 1
- IZBGCQRFUXWYDP-UHFFFAOYSA-N 6,7-dichloro-2-methyl-2-phenyl-1,3-dihydroindene-1,5-diol Chemical compound C1C2=CC(O)=C(Cl)C(Cl)=C2C(O)C1(C)C1=CC=CC=C1 IZBGCQRFUXWYDP-UHFFFAOYSA-N 0.000 description 1
- HBPVGJGBRWIVSX-UHFFFAOYSA-N 6-bromohexanoyl chloride Chemical compound ClC(=O)CCCCCBr HBPVGJGBRWIVSX-UHFFFAOYSA-N 0.000 description 1
- BUASXIXONFQIHR-UHFFFAOYSA-N 6-chloro-1-(2,3-dichloro-4-methoxyphenyl)-2-methylidenehexan-1-one Chemical compound COC1=CC=C(C(=O)C(=C)CCCCCl)C(Cl)=C1Cl BUASXIXONFQIHR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- AYVGBNGTBQLJBG-UHFFFAOYSA-N [3-(hydroxymethyl)cyclopentyl]methanol Chemical compound OCC1CCC(CO)C1 AYVGBNGTBQLJBG-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- RSJLWBUYLGJOBD-UHFFFAOYSA-M diphenyliodanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[I+]C1=CC=CC=C1 RSJLWBUYLGJOBD-UHFFFAOYSA-M 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PEHSSTUGJUBZBI-UHFFFAOYSA-N indan-5-ol Chemical class OC1=CC=C2CCCC2=C1 PEHSSTUGJUBZBI-UHFFFAOYSA-N 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/75—Reactions with formaldehyde
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Description
(19) DANMARK V2:3^' *
if:? I
» (12) FREMLÆGGELSESSKRIFT ød 1U4560B
DIREKTORATET FOR PATENT- OG VAREMÆRKEVÆSENET
(21) Ansøgning nr. 5^68/74 (51) IntCI.3 C 07 C 59/72 (22) Indleveringsdag 26. S ep. 1974 (24) Løbedag 26. sep. 1974 (41) Aim. tilgængelig 15· apr. 1975 (44) Fremlagt 29· tnar. 1982 (86) International ansøgning nr. -(86) International indleveringsdag -(85) Videreførelsesdag -(62) Stamansøgning nr. -
(30) Prioritet 12. okt. 1973* 40=965* US 51- jul. 1974, 492944, US
(71) Ansøger MERCK & CO. INC., Rahway, US.
(72) Opfinder Edward Jethro Cragoe Jr., US: Otto William Wolters= dorf Jr., US.
(74) Fuldmægtig ingeniørfirmaet Hofman-Bang & Boutard.
(54) Analogifremgangsæåde til frera= stilling af (1-hydroxy-5-inda= nyloxy)eddikesyrer eller salte deraf med baser.
Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af hidtil ukendte biologisk aktive (l-hydroxy-5-indanyloxy)-eddikesyrer med den i krav 1 angivne almene formel I eller ugiftige, pharmakologisk acceptable salte deraf med baser. Disse forbindelser udviser diuretisk, saluretisk og hypourecemisk aktivitet.
qj De ved fremgangsmåden ifølge opfindelsen fremstillede aktive for- q bindeiser er ugiftige og er velegnede til behandling af sygdomme, UD der er ledsaget af tilbageholdelse af elektrolytter og væske.
LO
-ft *
O
^ Forbindelserne egner sig også til behandling af hypertension. Des uden kan forbindelserne opretholde urinsyrekoncentrationen i lege- 2 144560 met på et forud bestemt niveau, eller de kan endog bevirke en formindskelse af urinsyrekoncentrationen.
Forbindelserne kan indgives i terapeutiske doser i de sædvanlige bæremedier, og de er i så fald effektive til reduktion af mængden af natrim- og chloridioner i legemet samt til at uddrive væsker, hvorved de kan benyttes til behandling af ødemer. De er endvidere befriet for hovedparten af de ulemper, der er knyttet til mange af de hidtil kendte diuretiske og salmetiske midler. Mange af de hidtil kendte diuretiske og saluretiske midler har således en tilbøjelighed til ved indgift at inducere hyperurecemia, hvorved der kan udskilles urinsyre eller natriumurat eller begge dele i legemet, og hvorved der kan opstå gigttilstande i forskellige stadier. Forbindelserne egner sig derfor især til behandling af patienter, hvor man skal undgå risikoen for at indføre gigtsygdomme .
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser er som nævnt aktive diuretiske og saluretiske midler. Desuden kan de opretholde urinsyrekoncentrationen i blodet på et forudbestemt niveau eller endog forårsage en formindskelse af urin-syrekoncentrationen. Forbindelserne kan indgives i forskellige terapeutiske doser i de sædvanlige bæremedier, f.eks. ved oral indgift i form af tabletter eller ved intravenøs injektion. Dosisstørrelsen kan variere inden for et stort område, f.eks. fra 5-1000 mg aktiv bestanddel,hvilke doser ligger under den giftige eller letale dosis af produkterne.
Det er kendt, at lignende forbindelser har diuretisk og uricosurisk aktivitet, se dansk patentansøgning nr. 4885/72, nr. 5257/73 og nr. 5258/73, men de derfra kendte forbindelser har ikke samme høje aktivitet som de ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser.
Fremgangsmåden ifølge opfindelsen, der er ejendommelig ved det i den kendetegnende del af kravet angivne, omfatter to udførelsesformer. Ved den ene af disse omsættes en halogeneddikesyre eller en r r ester deraf med formlen: ZCHgCOOR, hvor R er hydrogen eller lavere alkyl, såsom methyl eller ethyl, og Z er halogen, såsom brom, chlor eller iod, med en tilsvarende 5-hydroxy-l-indanol. .Følgende ligning illustrerer denne reaktion: 3 144560
Cl OH Cl OH
cl'^r^yC\ CV
R ZCH2C00R6 I |J r1 E</%J VoOCCh/N^-
II
Ib når R^ = lavere alkyl V Hydrolyse Fri Syre Ί & hvor R, R , R og Z har den ovennævnte betydning. Reaktionen udføres i nærværelse af en base, såsom alkalimetalcarbonat, hydroxid eller alkoxid, f.eks. kaliumcarbonat, natriumcarbonat, kaliumhydroxid, natriumhydroxid eller natriumethoxid. Der kan anvendes et vilkårligt opløsningsmiddel, som er inert eller i det væsentlige inert over for reagenserne, og hvori reagenserne har en passende opløselighed. Acetone, ethanol og dimethylformamid har f.eks. vist sig som særligt hensigtsmæssige opløsningsmidler. Reaktionen kan udføres ved en temperatur mellem 25°C og kogepunktet for det pågældende opløsningsmiddel. Reaktionen med halogeneddikesyren eller esteren er sædvanligvis afsluttet i løbet af 10 - 60 minutter. Hvis der anvendes en halogeneddikesyreester, hydrolyseres esteren til den frie syre på i og for sig kendt måde.
En anden metode til fremstilling af slutprodukterne I består i behandling af en tilsvarende 1-oxo-forbindelse (III) med et reduktions-middel, såsom natrium- eller kaliumborhydrid. Reaktionen udføres f. eks. under anvendelse af vand eller en blanding af methanol og vand som opløsningsmiddel, idet der f.eks. anvendes temperaturer mellem 5 og 50°C. Reaktionen illustreres af følgende skema: 4 144560
Cl O Cl OH
VAi ViV
S- v hoocch2o H00CCH20
III I
De omhandlede forbindelser (I) indeholder to asymmetriske carbon-atomer, nemlig i stillingerne 1 og 2 i indanylringen. Som følge heraf findes diastereomere, der kan adskilles på kendt måde, og de optiske antipoder kan skilles som angivet i det efterfølgende. Opfindelsen omfatter således ikke blot fremstillingen af racemiske (l-hydroxy-5-indanyloxy)eddikesyrer, men også deres optisk aktive antipoder .
Adskillelsen af de optiske isomere af de racemiske syrer (i) kan udføres ved dannelse af et_salt af den racemiske blanding med en optisk aktiv base, såsom (+) eller (-) amphetamin, (-)-cinchonidin, dehydroabiethylamin, (+) eller (-)-a-methylbenzylamin, (+) eller (_)_a-(l-naphthyl)-ethylamin, brucin eller strychnin, i et egnet opløsningsmiddel, såsom methanol, ethanol, 2-propanol, benzen, acetonitril, nitromethan eller acetone. På denne måde fås i opløsningen to diastereomere salte, hvoraf det ene sædvanligvis er lettere opløselig i opløsningsmidlet end det andet. Gentagne omkrystallisationer af det krystallinske salt giver sædvanligvis en ren diastereomer. Den optisk rene (l-hydroxy-5-indanyloxy)-eddikesyre fås ved syrning af salte med en m.ineralsyre, ex-traktion i ether, afdampning af opløsningsmidlet om omkrystallisation af den optisk rene antipode.
Den anden optisk rene antipode kan sædvanligvis fås ved anvendelse af en anden base til dannelse af et diastereomert salt. Det er hensigtsmæssigt at isolere den partielt spaltede syre fra filtratet efter fraskillelsen af det ene diasteromere salt og. yderligere at rense dette stof ved anvendelse af en anden optisk aktiv base.
I stedet kan mellemproduktet 5-indanolerne (II) adskilles i deres rene diastereomere, hvorefter de spaltes til deres rene antipoder før omdannelsen til de omhandlede forbindelser (I).
5 144560
Fremgangsmåden ifølge opfindelsen skal i det efterfølgende illustreres nærmere ved hjælp af nogle eksempler.
EKSEMPEL 1
Præparation af (l-Hydroxy-2-ethvl-6,7-dichlor-5-indanyloxy)eddikesyre
En suspension af (l-oxo-2-ethyl-6,7-dichlor-5-indanyloxy)eddikesyre (12,12 g, 0/04 mol) i vand (400 ml) omrøres og afkøles til 5 °C og behandles i 1 time med en opløsning af kaliumborhydrid (4,0 g, 0,075 mol) i vand (200 ml). Reaktionsblandingen omrøres i 1 time og gøres derefter sur med saltsyre, hvorved fås 10»·6 g (87$) (1-hydroxy-2-ethyl-6,7-dichlor-5-indanyloxy)eddikesyre, der smelter ved 121-122°C efter omkrystallisation af benzen.
Beregnet: C^H-^C^O^ c> 51,17; H, 4,62; Cl, 23,24 Fundet: C, 51,30,- H, 4,39; Cl, 23,05 EKSEMPEL 2
Præparation af /1'-Hydroxy-6’,7’-dichlorspiro-(cyclopentan-1,2'-indan)-5*-vloxv7eddikesyre_
Trin A: 2,3-Dichlor-4-(6-bromhexanoyl)anisol
En blanding af 2,3-dichloranisol (89 g, 0 ,50 mol) og 6-bromhexa-noylchlorid (120 g, 0-59 mol) i methylenchlorid (500 ml) omrøres og afkøles til 5°C og behandles med aluminiumchlorid (74 g, 0, 56 mol) i portioner i løbet af en halv time. Reaktionsblandingen holdes ved 25°C i 18 timer, hældes derefter i 1 liter isvand indeholdende 100 ml saltsyre. Den organiske fase fraskilles, vaskes med vand, 2% natriumhydroxid og fortyndet saltsyre. Methylen-chloridet afdampes ved reduceret tryk, den olieagtige remanens opløses i ether, tørres over magnesiumsulfat, inddampes til 200 ml og behandles med hexan (600 ml), hvorved fås 2,3-dichlor-4-(6-bromhexanoyl)anisol, som smelter ved 52-53°C.
Beregn, for ci3Hi5BrC12°2: C, 44,10; H, 4,27 Fundet C, 44,33; H, 4,66.
Trin B; 2-(4-Chlorbutyl)-5-methoxv-6.7-dichlor-l-indanon 6 144560
En blanding af 2,3-dichlor-4-(β-bromhexanoyl)anisol (10 g), dimethyl-amin-hydrochlorid (4 g), paraformaldehyd (2 g) og eddikesyre (0,5 ml) opvarmes på dampbad i 2 timer, behandles med 30 ml di-methylformamid og opvarmes i yderligere 2,5 timer. Reaktionsblandingen hældes i vand, extraheres med ether, vaskes med vand og tørres over magnesiumsulfat. Ved afdampning af etheren fås 9 g urenset 2,3-dichlor-4-(6-chlor-2-niethylenhexanoyl)anisol', som cycliseres ved behandling med koncentreret svovlsyre (50 ml). Svovlsyre opløsningen hældes i vand (300 ml), hvorved fås 5»8 g 2-(4-chlorbutyl)-5-methoxy-6,7-dichlor-l-indanon, der smelter ved 92°C efter omkrystallisation af cyclohexan.
Elementaranalyse for C14H15C13°2:
Beregn.: C, 52,28; H, 4,70; Cl, 33,07;
Fundet: C, 52,25; H, 4,50; Cl, 33,03.
Trin C: 5'-Methoxy-6*,7*-dichlorspiro-(cyclopentan-1,2'-indanon\
En suspension af natriumhydrid (370 mg, 0,0155 mol) i 1,2-dimethoxy-ethan (250 ml) omrøres og koges under tilbagesvaling i en inert atmosfære. En opløsning af 2-(4-chlorbutyl)-5-methoxy-6,7-dichlor- 1-indanon (4,5 g, 0,014 mol) i 1,2-dimethoxyethan (50 ml) tilsættes i løbet af 20 minutter, og kogningen under tilbagesvaling opretholdes i 3 timer. Opløsningsmidlet afdestilleres til et rumfang på 50 ml, og denne destillationsrest hældes i 300 ml vand, hvorved fås 2,6 g 5’-methoxy-61,7’-dichlorspiro-(cyclopentan-1,2*-indanon), der smelter ved 170°C efter omkrystallisation af ethanol-vand.
Elementaranalyse for C14H14C12°2:
Beregn.: C, 58,97; H, 4,85;
Fundet: C, 59,34; H, 5,08.
Trin D: 5*-Hydroxy-6*,7*-dichlorspiro-(cyclopentan-1,21-indanon)
En blanding af 5’-methoxy-61,7’-dichlorspiro-(cyclopentan-1,2’- indanon) (2,6 g, 0,0091 mol) og pyridin-hydrochlorid (26 g) opvar mes under omrøring til 185°C i 1 time og hældes derefter i vand 7 144560 (200 ml). Det udskilte 5’-hydroxy-6’,7'-dichlorspiro-(cyclopentan-1,2’-indanon) (2,3 g) smelter ved 236°C efter omkrystallisation af nitromethan.
Elementaranalyse for ci3Hi2C12°2:
Beregn.: C, 37,55; H, 4,46;
Fundet: C, 57,77; H, 4,54.
Trin E: 6», 7 ^Dichlorspiro-(cyclopentan-l. 2^^0^-11,5'-άϊο1
En opløsning af 5'-hydroxy-61,7'-dichlorspiro-(cyclopentan-1,2'-indanon) (8,1 g, 0,03 mol) i tetrahydrofuran (100 ml) afkøles under omrøring til 15°C og behandles i løbet af 5 minutter med en opløsning af natrium-bis-(2-methoxyethoxy)aluminiumhydrid (10 ml 70$ benzenopløsning). Reaktionsblandingen omrøres i en halv time ved 25°C, afkøles til 10°C og behandles langsomt med 20% vandig saltsyre, indtil reaktionen er sur. Den organiske fase inddampes til dannelse af en olie, som opløses i ether, vaskes med vand, tørres over magnesiumsulfat, og opløsningsmidlet afdampes til dannelse af 6,5 g 6' ,7'-dichlorspiro-(cyclopentan-1,2’-indan)-1' ,5'-diol.
Beregn, for C, 57,16; H, 5,17;
Fundet: C, 57,46; H, 5,20.
Trin F: jl1-Hydroxy-6’,7'-dichlorspiro(cyclopentan-1,2’-indan)- 5 »_yloxy7eddikesyre_
En blanding af 6T,7'-dichlorspiro-(cyclopentan-1,2'-indan)-l',51 -diol (4,1 g, 0,015 mol), kaliumcarbonat (3,6 g) og ethylbromacetat (3Ί ml) i dimethylformamid (35 ml) opvarmes under omrøring til 55°C i 1/2 time i en inert atmosfære;, behandles med vand (45 ml)
Og IC N natriumhydroxid (5 ml) og opvarmes dernæst ved 95 °C i 20 minutter og hældes i isvand (200 ml) indeholdende 10 ml saltsyre Dette udskilte D-' -hydroxy-6T,7’-dichlorspiro-(cyclopentan-1,2’-indan)-5’-y10x^7eddikesyre smelter ved 135°C efter omkrystallisation af benzen.
Beregn, for c45Hi6cl2°4: c> 54,40; H, 4,87; Cl, 21,41 Fundet: C, 54,03; H, 5,19 Cl, 21,47.
8 144560
Elementaranalyse for Ci7H20C12°4:
Beregn.: C, 5β,83; H, 5,61;
Fundet: C, 57,14; H, 5,69.
EKSEMPEL 3 (l-Hvdroxy-23-phenvl-2a-methyl-6«7-dlchlor-5-indanyloxy)-eddikesyre
Trin A: 2-Phenyl-2-methyl-5-methoxy-6.7-dichlor-l-indanon
Kalium-tert-butoxid (8,42 g, 0,075 mol) i tør tert-butylalkohoL (300 ml) sættes til en kogende opløsning af 2-methyl-5-methoxy- 6,6-dichlor-l-indanon, (12,26 g, 0,05 mol), i 50 ml benzen. Efter kogning under tilbagesvaling i 2 timer tildryppes en suspension af diphenyliodoniumchlorid (19,0 g, 0,06 mol) i 1 liter tert-butylalko-hol. Efter kogning under tilbagesvaling i yderligere 2 timer afkøles blandingen, 300 ml vand tilsættes, og blandingen inddampes til tørhed i vakuum, hvorved fås 4,97 g 2-phenyl-2-methyl-5-methoxy-6,7-dichlor-l-indanon, der smelter ved 161-163°C efter omkrystallisation af benzen :cyclohexan, 1:2.
Trin B: 2-Phenyl-2-methvl-5-hydroxy-6,7-dichlor-l-indanon 2-Phenyl-2-methyl-5-methoxy-6,7-dichlor-l-indanon (4,94 g, 0,015 mol) blandes med 50 g pyridinhydrochlorid, og blandingen opvarmes til 175°C i 1 time, hældes derefter i 500 ml vand, og produktet opsamles, omkrystalliseres af en blanding af ethanol og vand i -forholdet 2:1 til dannelse af 2-phenyl-2-methyl-5-hydroxy-6,7-dichlor-l-indanon, smp 194-196 °C.
Trin C: 2-Methyl-2-phenyl-6,7-dichlorindan-l,5-diol (2a- og 2β- isomere)_
Til en opløsning af 2-methyl-2-phenyl-5-hydroxy-6,7-dichlor-l-indanon (14,3 g, 0,047 mol) i tetrahydrofuran (150 ml) under nitrogen dryppes i løbet af 10 minutter 70% natrium-bis(2-methoxy-ethoxy)-aluminiumhydrid i benzen (17 ml) i tetrahydrofuran (50 ml), medens reaktionstemperaturen holdes på 10-15°C. Reaktionsblandingen omrøres ved 25°C i 26 timer, afkøles til 10°C, behandles langsomt med 10% saltsyre, indtil skumningen ophører, derefter 9 144560 med 20% saltsyre til sur reaktion. Tetrahydrofuranen dekanteres fra en pastaagtig remanens, inddampes til tørhed, og remanensen optages i 300 ml benzen. Det uopløselige homogene produkt, der udskilles på dette trin, består hovedsageligt af 2p-methyl-2a-phenyl-6,7-dichlorindan.-l,5-diol 800 mg, smp: 177-181°C. Benzenopløsningen tørres over magnesiumsulfat og inddampes til tørhed, hvorved fås 8,57 g af en blanding af de isomere. Tre omkrystallisationer af benzen giver 3,0 g 2a-methyl-2iJ-phenyl-6,7-di-chlorindan-l,5-diol, smp.: 163-165 °C, der anvendes i det følgende uden yderligere rensning.
Trin D (l-Hydroxy-2a-methyl-2(3-phenyl-6,7-dichlor-5-indanyloxy)-eddikesyre_
En blanding af 2ofc-methyl-2p,-phenyl-6,7-dichlorindan-l, 5-diol ( 3,00 g, 0,0097 mol), kaliumcarbonat (2,68 g, 0,0194 mol) og ethylbromace-tat (3,24 g, 0,0194 mol) i dimethylformamid (60 ml) opvarmes til 55-60 °C i 2,5 timer, behandles derefter med 60 ml vand og 10 N natriumhydroxidopløsning (4 ml, 0,04 mol) og opvarmes til 100 °C i 1 time. Reaktionsblandingen hældes i en opløsning af isvand (600 ml) og 12 N saltsyre (20 ml) til udfældning af 920 mg (1-hydroxy-2h,-methyl-2 |i~phenyl-6,7-dichlor-5-indanyloxy) eddikesyre, som smelter ved 160-162 °C efter omkrystallisation af benzen :hexan, 1:1.
Elementaranalyse for C-^H-^CH^O^:
Beregn.: C, 58,55; H, 4,91;
Fundet: C, 58,85; H, 4,50.
Nogle typiske forbindelser, fremstillet ved fremgangsmåden ifølge opfindelsen, blev testet for diuretisk og uricosurisk aktivitet ved følgende procedure:
Fastende han-chimpanser med en vægt på 21-27 kg blev immobiliseret med phencyclodin (hvilket viste sig uden virkning på resultaterne) (1,0 - 1,5 mg/kg im plus 0,25 mg/kg iv om fornødent) og blev forberedt til kateterisation for standard renal udtømningsundersøgelse ved den sædvanlige kliniske aseptiske procedure. Pyrogenfrit inu-lin (iv) anvendtes til måling af glomerulær filtreringshastighed (GFR). Udtømning af inulin, urat og udskilningshastighed for Na+, K+ og Cl- blev bestemt ved standard autoanalyse (inulin og urat i 10 144560 chimpanse-plasma er frit filtrerbart). Gennemsnitlig kontrol-udtømning blev beregnet fra tre efter hinanden følgende 20 min. perioder. Værdier for lægemiddel-respons blev bestemt som gennemsnit af otte 15 - 20 min. udtømningsperioder efter oral indgift af en vandig opløsning af forbindelsen gennem et nasalt kateter. Alle data bestemtes som difference mellem (middel)værdier for behandling og kontrol, opnået fra enkelte forsøg.
De diuretiske (D) og uricosuriske (U) data for chimpanser er angivet ved et point-system på følgende måde:
Data for diuretisk test på chimpansen blev oprindeligt beregnet C c som en ΛyU ækv./lin., og urat-data er målt som Δ urat/ inulin.
De opnåede points-værdier er følgende:
Diuretisk aktivitet Urecosurisk aktivitet P c
Points AyU ækv./min. Points ^ urat/ inulin 0 0 - 49 0 0 - 0,05 - 50-99 - 0,05 - 0,09 1 100 - 199 1 0,1 - 0,19 2 200 - 299 2 0,2 - 0,29 3 300 - 399 3 0,3 - 0,39 4 400 - 499 4 0,4 - 0,49 5 500 - 599 5 0,5 - 0,59 >5 > 600
Alle doser var på 5 mg/kg po (oralt).
I efterfølgende tabel er angivet resultaterne af nogle bestemmelser af aktiviteten for forbindelser fremstillet ved fremgangsmåden ifølge opfindelsen i sammenligning med andre, meget nært beslægtede forbindelser, der er uvirksomme.
Cl OH
Cl i I R
o R
H0CCH20 ^
Claims (1)
11 144560 Forb. R R1 Chimp 5 PO nr. D U l] fremstillet C?Hb H 3 1 Jiilg.op£. 5 2 5J p-CgH5 a-OHj 4 0 2W.- (ch2)2oh3 H 0 ± 4. forbindel- cc-CH3 2 i 6y ser a-C6H5 <# CH3 0 1 Patentkrav : Analogifremgangsmåde til fremstilling af (l-hydroxy-5-indanyloxy)-eddikesyrer med den almene formel: “AV- H00CCH20 ^ hvor R er ethyl eller β-phenyl, R^ er hydrogen eller methyl, eller R og R^· sammen med det tilknyttede carbonatom danner en cyclopentyl-gruppe, eller ugiftige, pharmakologisk acceptable salte deraf med baser, kendetegnet ved, at a) en forbindelse med formlen: Cl pH Cl 11 ,R ^ If r1 11 hvor R og R·*· har den ovennævnte betydning, omsættes med en forbindelse med formlen: zch2coor6
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40596573A | 1973-10-12 | 1973-10-12 | |
| US40596573 | 1973-10-12 | ||
| US49294474A | 1974-07-31 | 1974-07-31 | |
| US49294474 | 1974-07-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK506874A DK506874A (da) | 1975-06-09 |
| DK144560B true DK144560B (da) | 1982-03-29 |
| DK144560C DK144560C (da) | 1982-09-27 |
Family
ID=27019308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK506874A DK144560C (da) | 1973-10-12 | 1974-09-26 | Analogifremgangsmaade til fremstilling af (1-hydroxy-5-indanyloxy)eddikesyrer eller salte deraf med baser |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5077354A (da) |
| CH (1) | CH614691A5 (da) |
| DE (1) | DE2448395A1 (da) |
| DK (1) | DK144560C (da) |
| ES (1) | ES430901A1 (da) |
| FR (1) | FR2247216B1 (da) |
| GB (1) | GB1475907A (da) |
| NL (1) | NL7412826A (da) |
| SE (1) | SE421305B (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2322859A (en) * | 1995-12-06 | 1998-09-09 | Venantius Limited | Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity |
-
1974
- 1974-09-25 SE SE7412048A patent/SE421305B/xx unknown
- 1974-09-26 DK DK506874A patent/DK144560C/da active
- 1974-09-27 NL NL7412826A patent/NL7412826A/xx not_active Application Discontinuation
- 1974-10-07 GB GB4337674A patent/GB1475907A/en not_active Expired
- 1974-10-08 FR FR7433811A patent/FR2247216B1/fr not_active Expired
- 1974-10-10 ES ES430901A patent/ES430901A1/es not_active Expired
- 1974-10-10 DE DE19742448395 patent/DE2448395A1/de not_active Ceased
- 1974-10-10 CH CH1366074A patent/CH614691A5/xx not_active IP Right Cessation
- 1974-10-11 JP JP49116991A patent/JPS5077354A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK144560C (da) | 1982-09-27 |
| SE7412048L (da) | 1975-04-14 |
| AU7391474A (en) | 1976-04-08 |
| NL7412826A (nl) | 1975-04-15 |
| FR2247216A1 (da) | 1975-05-09 |
| DK506874A (da) | 1975-06-09 |
| FR2247216B1 (da) | 1978-02-03 |
| ES430901A1 (es) | 1977-03-16 |
| SE421305B (sv) | 1981-12-14 |
| CH614691A5 (en) | 1979-12-14 |
| JPS5077354A (da) | 1975-06-24 |
| GB1475907A (en) | 1977-06-10 |
| DE2448395A1 (de) | 1975-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0281459B1 (fr) | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant | |
| US4070539A (en) | [1-Oxo-2-halo(or hydrogen) indanyloxy]-alkanoic acid | |
| FR2576901A1 (fr) | Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique | |
| DK141063B (da) | Analogifremgangsmåde til fremstilling af 1-oxo-5-indanyloxyeddikesyrer eller salte deraf med baser. | |
| US2398418A (en) | Introduction of organic radicals into quinones | |
| FR2554817A1 (fr) | Nouveaux derives de la vinyl-6 furo-(3,4-c)-pyridine ainsi que leur procede de preparation | |
| NO743534L (da) | ||
| DK143339B (da) | Analogifremgangsmaade til fremstilling af 6-oxo7,7-disubstitueret-1,2,7,8-tetrahydro-6h-indeno (5,4-b) furan-2-carboxylsyrer | |
| DK146444B (da) | Analogifremgangsmaade til fremstilling af 1-oxo-2,3-hydrocarbylen-5-indanyloxy-eddikesyrer eller salte deraf med baser | |
| US4234742A (en) | Bis-(aryloxycarboxylic acid) compounds | |
| DK144560B (da) | Analogifremgangsmaade til fremstilling af (1-hydroxy-5-indanyloxy) eddikesyrer eller salte deraf med baser | |
| GB1587084A (en) | Thiophene derivatives | |
| US3506658A (en) | 2-(10-methyl-2-phenoxazinyl)propionic acid | |
| JP3305447B2 (ja) | R/S−γ−リポ酸またはR/S−α−リポ酸の製造法、8−アルコキシ−6−ホルミルオキシオクタン酸およびその製造法 | |
| US3325515A (en) | Coumarin derivatives and their preparation | |
| NO790948L (no) | Fremggangsmaate for fremstilling av dilignolderivater | |
| US2993891A (en) | Butyrolactone derivatives | |
| US5489592A (en) | 3,4-dihydro-4-oxo-3-(2-propenyl)-1-phthalazineacetic acids and derivatives, their preparations and medicines containing them | |
| CA1241336A (en) | Process for the preparation of arylalkanoic acids by oxidative rearrangement of arylalkanones | |
| US4247715A (en) | 2-Alkynyl-5-indanyloxyacetic acids | |
| CH392483A (fr) | Procédé de préparation de nouveaux esters d'acides 4-halo-3-sulfamoyl-benzoïques | |
| US2797227A (en) | Basic esters of 2-norcamphanecarboxylic acid and of bicyclo [2. 2. 2]-octane-2-carboxic acids, their salts, and nuclearly alkylated substitution products thereof | |
| FR2478640A1 (fr) | Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique | |
| NO146136B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive indanderivater. | |
| SU1454250A3 (ru) | Способ получени солей эфедрина с аналогами 7-оксо-PGJ @ |